CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
12985056,1298505611,11,F,,20240916,20161129,20240927,EXP,,CA-APOTEX-2016AP014805,APOTEX,,52,YR,,M,Y,,,20240927,,MD,CA,CA,EFAVIRENZ,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,1298505611,OT,,,1298505611,1,,,9668,DAY,1298505611,1,HIV infection
14492178,144921783,3,F,,20180202,20180206,20240923,EXP,,UG-MYLANLABS-2018M1007722,MYLAN,,,,,M,Y,2.5,KG,20240923,,HP,UG,UG,EFAVIRENZ,Congenital knee dislocation;Congenital musculoskeletal disorder of skull;Developmental hip dysplasia;Foetal exposure during pregnancy;Joint stiffness;Micrognathia;Talipes;Wrist deformity,144921783,CA,,,144921783,1,20171206,,,,144921783,1,Product used for unknown indication
16020890,1602089027,27,F,,20240801,20190301,20240814,EXP,,CA-AUROBINDO-AUR-APL-2019-010743,AUROBINDO,"Harris M, Larsen G, Montaner JSG.. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22(14):1890-2",54,YR,,M,Y,,,20240814,,HP,CA,CA,EFAVIRENZ,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Paranoia;Prescribed overdose;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,1602089027,HO,,,,,,,,,1602089027,1,HIV infection
16022512,1602251211,11,F,,20240829,20190301,20240909,EXP,,CA-AUROBINDO-AUR-APL-2019-010641,AUROBINDO,"Pfeffer G, Mezei MM, Montaner JS, Li CC, Jitratkosol M, Cote HC. Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. NEUROLOGY. 2009;73 (1):71-2",52,YR,,M,Y,,,20240909,,HP,CA,CA,EFAVIRENZ,Aphasia;Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,1602251211,CA,,,1602251211,1,,,91,DAY,1602251211,1,HIV infection
16623814,166238143,3,F,,20240827,20190724,20240905,EXP,,CA-AUROBINDO-AUR-APL-2019-042064,AUROBINDO,,54,YR,,M,Y,,,20240905,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction,166238143,OT,,,,,,,,,166238143,1,Bipolar disorder
17044956,1704495619,19,F,,20240925,20191118,20240930,EXP,,CA-BAUSCH-BL-2019-058588,BAUSCH AND LOMB,"Harris M, Larsen G, Montaner J. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22 (14):1890-1892. doi:10.1097/QAD.0b013e32830e0169",54,YR,,M,Y,,,20241001,,HP,CA,CA,EFAVIRENZ,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Paranoia;Prescribed overdose;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,1704495619,DE,,,1704495619,70,,,4,YR,1704495619,1,Bipolar disorder
17359956,173599565,5,F,20090428,20240910,20200203,20240916,PER,,US-GILEAD-2020-0448795,GILEAD,,54,YR,A,M,Y,99.773,KG,20240916,,LW,US,US,EFAVIRENZ,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain;Renal failure,173599565,HO,,,173599565,1,2004,20090312,717,DAY,173599565,1,HIV infection
17743771,177437715,5,F,,20240628,20200505,20240710,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020GSK075602,VIIV,,,,,,Y,,,20240710,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,177437715,DE,,,,,,,,,177437715,1,HIV infection
17743782,177437825,5,F,,20240628,20200505,20240702,EXP,,CA-GLAXOSMITHKLINE-CA2020GSK075602,GLAXOSMITHKLINE,,,,,,Y,,,20240702,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,177437825,DE,,,,,,,,,177437825,1,HIV infection
18886438,188864382,2,F,,20240718,20210212,20240726,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013434,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20240726,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,188864382,OT,,,,,,,,,188864382,1,Product used for unknown indication
19312818,193128183,3,F,,20240716,20210527,20240725,EXP,,CA-APOTEX-2021AP012394,APOTEX,,,,,M,Y,,,20240725,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,193128183,OT,,,,,,,,,193128183,1,Product used for unknown indication
19525161,195251612,2,F,,20240726,20210712,20240808,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-066036,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20240808,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,195251612,OT,,,,,,,,,195251612,1,Product used for unknown indication
20858432,208584329,9,F,,20240802,20220521,20240808,EXP,,CA-009507513-2205CAN005476,MERCK,,54,YR,,M,Y,,,20240808,,HP,CA,CA,EFAVIRENZ,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208584329,HO,,,,,,,,,208584329,1,HIV infection
20892665,208926659,9,F,,20240923,20220531,20240927,EXP,,CA-ABBVIE-22K-028-4414704-00,ABBVIE,,54,YR,,M,Y,,,20240927,,HP,CA,CA,EFAVIRENZ,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208926659,OT,,,,,,,,,208926659,1,HIV infection
20898441,208984419,9,F,,20240801,20220601,20240815,EXP,,CA-AUROBINDO-AUR-APL-2022-018761,AUROBINDO,,54,YR,,M,Y,,,20240815,,HP,CA,CA,EFAVIRENZ,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208984419,OT,,,,,,,,,208984419,1,Psychotic disorder
20929340,209293402,2,F,20171006,20240715,20220608,20240722,EXP,,GB-AUROBINDO-AUR-APL-2022-020239,AUROBINDO,,43,YR,,F,Y,,,20240722,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy,209293402,OT,,,209293402,1,20171006,20180205,4,MON,209293402,1,HIV infection
21361888,213618884,4,F,,20240801,20220922,20240814,EXP,,CA-AUROBINDO-AUR-APL-2022-037540,AUROBINDO,"Harris M, Larsen G, Montaner J. Exacerbation of depression associated with starting raltegravir: A report of four cases. AIDS. 2008;22(14):1890-1892",44,YR,,M,Y,,,20240814,,MD,CA,CA,EFAVIRENZ,Depression;Drug interaction;Psychiatric decompensation,213618884,HO,,,213618884,4,,,354,DAY,213618884,1,Depression
21738852,217388523,3,F,,20240723,20221216,20240805,EXP,,US-CIPLA LTD.-2022US07155,CIPLA,"Kilcrease C, Agwu AL, Yusuf H, Park J, Powell A, James L et al.. Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series. AIDS Research and Therapy. 2022;19 (56):1 to 6",,,,,Y,,,20240805,,HP,US,US,EFAVIRENZ,Adverse drug reaction;Drug resistance;Immunosuppression;Infection;Mucocutaneous candidiasis;Nausea;Onychomycosis;Oral candidiasis;Pneumonia;Product use complaint;Pyelonephritis;Somnolence;Treatment noncompliance;Varicella;Virologic failure,217388523,OT,,,,,,,,,217388523,1,HIV infection
23776671,237766712,2,F,,20240827,20240424,20240902,EXP,,US-CIPLA (EU) LIMITED-2024US03893,CIPLA,"Woods HB, Bharathidasan K, Yang M, Nichols J, Nugent K.. Delayed onset graves disease following initiation of antiretroviral therapy in patients with human immunodeficiency virus: A case series. The American Journal of the Medical Science. 2024;367 (S1):S9 to S10",,,,,Y,,,20240902,,MD,US,US,EFAVIRENZ,Endocrine ophthalmopathy;Graves' disease,237766712,OT,,,,,,,,,237766712,1,HIV infection
23824661,238246612,2,F,20231009,20240805,20240507,20240812,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2023EME167263,VIIV,,,,,,Y,,,20240812,,MD,DE,DE,TENOFOVIR + EMTRICITABINE + EFAVIRENZ,Pathogen resistance;Viral mutation identified;Virologic failure,238246612,DS,,,238246612,1,20210805,20231009,795,DAY,238246612,1,HIV infection
24040572,240405721,1,I,,20240619,20240702,20240702,EXP,,US-CIPLA LTD.-2024US06678,CIPLA,"Nguyen NV, Kim L, Collins LF, Ofotokun I, Fernandes A, Yeh S et al. Retinopathy associated with Ritonavir treatment for HIV infection: a case series reappraisal in the COVID-19 era.. Journal of vitreoretinal diseases. 2024;8(1):111 to 116",,,,,Y,,,20240702,,HP,US,US,EFAVIRENZ,Maculopathy,240405721,OT,,,,,,,,,240405721,1,Antiretroviral therapy
24052292,240522921,1,I,20191001,20240626,20240704,20240704,EXP,,UG-PRINSTON PHARMACEUTICAL INC.-2024PRN00259,PRINSTON PHARMACEUTICAL,"Nambuya M, H Kizza M. A case report: recurrent anemia related to long term acyclovir use in a pregnant HIV infected Ugandan. African Health Sciences. 2024;24 (1):91-93",19,YR,,F,Y,,,20240704,,HP,UG,UG,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia megaloblastic;Malaria,240522921,HO,,,240522921,1,2019,2019,,,240522921,1,Anogenital warts
24053207,240532071,1,I,,20240627,20240705,20240705,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-2024-103202,BRISTOL MYERS SQUIBB,"Tambe S, Jangid K, Shinde G, Jadhav S, Mahobia S, Lala M, et al. Drug-induced systemic lupus erythematosus in a child living with HIV. Indian Journal of Sexually Transmitted Diseases and AIDS. 2024 Jun 06;45(1):59-61. doi:10.4103/ijstd.ijstd_69_23.",12,YR,T,M,Y,,,20240705,,HP,IN,IN,EFAVIRENZ,Lupus-like syndrome,240532071,HO,,,240532071,1,2019,,,,240532071,1,HIV infection
24059186,240591861,1,I,,20240624,20240708,20240708,EXP,,IN-CIPLA LTD.-2024IN06905,CIPLA,"Tambe S, Jangid K, Shinde G, Jadhav S, Mahobia S, Lala M, et.al. Drug-induced systemic lupus erythematosus in a child living with HIV. Indian Journal of Sexually Transmitted Diseases and AIDS. 2024;45 (1):59 to 61",,,,,Y,,,20240708,,HP,IN,IN,EFAVIRENZ,Lupus-like syndrome,240591861,HO,,,,,,,,,240591861,1,HIV infection
24064501,240645011,1,I,,20240702,20240709,20240709,EXP,,ZA-MYLANLABS-2024M1063699,MYLAN,"Khan A, Pillay M, Chimukangara B, Gounder L, Manyana S, Francois K-L, et al. Identification of HIV-1 subtype CRF18_cpx in a patient with multidrug resistance in KwaZulu-Natal, South Africa: An epidemiological worry?. J-Clin-Virol-Plus 2023; 3 (2):.",31,YR,,F,Y,,,20240709,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Diarrhoea;Pathogen resistance,240645011,HO,,,240645011,1,20170109,,,,240645011,1,HIV infection
24070760,240707601,1,I,20220901,20240314,20240710,20240710,PER,,PE-ROCHE-3528367,ROCHE,,35,YR,A,M,Y,74,KG,20240628,,MD,PE,PE,EFAVIRENZ,Proteinuria,,,,,240707601,1,20220505,20220912,3,DAY,240707601,1,Non-small cell lung cancer metastatic
24075720,240757201,1,I,,20240703,20240710,20240710,EXP,,DK-GSK-DK2024GSK083765,GLAXOSMITHKLINE,"Pedersen OS, Barkholt TO, Madsen SH, Rudolf F. Tuberculosis immune reconstitution syndrome (TB-IRIS) followed by recurring lymphadenitis up to 8 years post-antituberculous treatment. BMJ Case Reports. 2024;17 (6)",,,,,Y,,,20240710,,HP,DK,DK,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis;Lymphadenitis;Lymphadenopathy;Oral candidiasis;Pyrexia;Renal impairment,240757201,OT,,,,,,,,,240757201,1,HIV infection
24075728,240757281,1,I,,20240703,20240710,20240710,EXP,,DK-VIIV HEALTHCARE LIMITED-DK2024GSK083765,VIIV,"Pedersen OS, Barkholt TO, Madsen SH, Rudolf F. Tuberculosis immune reconstitution syndrome (TB-IRIS) followed by recurring lymphadenitis up to 8 years post-antituberculous treatment. BMJ Case Reports. 2024;17 (6)",,,,,Y,,,20240710,,HP,DK,DK,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis;Lymphadenitis;Lymphadenopathy;Oral candidiasis;Pyrexia;Renal impairment,240757281,HO,,,,,,,,,240757281,1,HIV infection
24089720,240897201,1,I,,20240702,20240715,20240715,EXP,,ZA-STRIDES ARCOLAB LIMITED-2024SP008069,STRIDES,"Khan A, Pillay M, Chimukangara B, Gounder L, Manyana S, Francois K-L, et al.. Identification of HIV-1 subtype CRF18_cpx in a patient with multidrug resistance in KwaZulu-Natal, South Africa: An epidemiological worry?.. J-Clin-Virol-Plus. 2023;3 (2)",31,YR,,F,Y,,,20240715,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Pathogen resistance;Treatment failure,240897201,OT,,,240897201,1,20170109,,,,240897201,1,HIV infection
24093974,240939742,2,F,20190101,20240711,20240716,20240724,EXP,,UG-MACLEODS PHARMA-MAC2024048131,MACLEODS,"Nambuya M, Mayanja-Kizza H.case report: recurrent anemia related to long term acyclovir use in a pregnant HIV infected Ugandan.African Health Sciences.2024;24(1):91-3",,,,,Y,,,20240724,,MD,UG,UG,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia megaloblastic;Maternal exposure during pregnancy;Self-medication,240939742,HO,,,240939742,1,2019,,,,240939742,1,Anogenital warts
24101321,241013212,2,F,,20240803,20240717,20240813,EXP,,KZ-HETERO-HET2024KZ02251,HETERO,,,,,M,Y,,,20240813,,HP,KZ,KZ,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Poisoning,241013212,OT,,,241013212,1,20240125,20240222,29,DAY,241013212,1,HIV infection WHO clinical stage I
24101731,241017312,2,F,,20240803,20240717,20240809,EXP,,KZ-HETERO-HET2024KZ02252,HETERO,,,,,F,Y,,,20240809,,HP,KZ,KZ,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Asthenia;Cough;Dizziness;Fatigue;Poisoning;Product dose omission issue,241017312,OT,,,241017312,1,20231106,20240214,101,DAY,241017312,1,HIV infection
24104618,241046181,1,I,,20240710,20240717,20240717,EXP,,IN-MYLANLABS-2024M1065941,MYLAN,"Tambe S, Jangid K, Shinde G, Jadhav S, Mahobia S, Lala M, et al. Drug-induced systemic lupus erythematosus in a child living with HIV. India-J-Sex-Transm-Dis 2024; 45 (1): 59-61.",12,YR,,M,Y,,,20240717,,MD,IN,IN,EFAVIRENZ,Systemic lupus erythematosus,241046181,HO,,,,,,,,,241046181,1,HIV infection
24104734,241047342,2,F,,20240723,20240717,20240731,EXP,,US-MYLANLABS-2024M1065887,MYLAN,"Bishop MD, Korutaro V, Boyce CL, Beck IA, Styrchak SM, Knowles K, et al. Characterizing HIV drug resistance in cases of vertical transmission in the VesTed randomized antiretroviral treatment trial. J-Acquir-Immune-Defic-Syndr 2024; 96 (4): 385-392.",,,I,,Y,,,20240731,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR\TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective,241047342,OT,,,,,,,,,241047342,1,Prophylaxis against HIV infection
24107199,241071992,2,F,,20240803,20240718,20240812,EXP,,KZ-HETERO-HET2024KZ02248,HETERO,,,,,M,Y,,,20240812,,HP,KZ,KZ,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Poisoning,241071992,OT,,,241071992,1,20210802,20240212,925,DAY,241071992,1,HIV infection WHO clinical stage II
24114771,241147711,1,I,,20240710,20240721,20240721,EXP,,IN-STRIDES ARCOLAB LIMITED-2024SP008730,STRIDES,"Tambe S, Jangid K, Shinde G, Jadhav S, Mahobia S, Lala M, et al.. Drug-induced systemic lupus erythematosus in a child living with HIV.. India-J-Sex-Transm-Dis. 2024;45(1):59-61",12,YR,,M,Y,,,20240719,,MD,IN,IN,EFAVIRENZ,Systemic lupus erythematosus,241147711,HO,,,,,,,,,241147711,1,HIV infection
24118659,241186591,1,I,,20240715,20240722,20240722,EXP,,IN-HETERO-HET2024IN02386,HETERO,"Tambe S, Jangid K, Shinde G, Jadhav S, Mahobia S, Lala M, et.al.. Drug-induced systemic lupus erythematosus in a child living with HIV. Indian Journal of Sexually Transmitted Diseases and AIDS.. 2024;45(1):59-61",12,YR,,M,Y,,,20240722,,HP,IN,IN,EFAVIRENZ,Systemic lupus erythematosus,241186591,HO,,,,,,,,,241186591,1,HIV infection
24120494,241204942,2,F,,20240730,20240722,20240802,EXP,GB-MHRA-MED-202407171329112380-FHGCW,GB-MYLANLABS-2024M1066883,MYLAN,,,,,F,Y,,,20240802,,HP,GB,GB,EFAVIRENZ,Choking,241204942,OT,,,,,,,,,241204942,1,Product used for unknown indication
24120939,241209391,1,I,,20240716,20240722,20240722,EXP,,ZW-MYLANLABS-2024M1068078,MYLAN,"Mandikiyana Chirimuta LA, Pascoe MJ, Lowe S. Emergent dolutegravir resistance in integrase-naive, treatment experienced patients from Zimbabwe. South-Afr-J-HIV-Med 2022; 23 (1): a1435.",29,YR,,F,Y,,,20240722,,HP,ZW,ZW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Drug interaction;Drug resistance mutation;Treatment failure,241209391,OT,,,241209391,1,201706,202006,,,241209391,1,HIV infection
24125317,241253171,1,I,,20240710,20240723,20240723,EXP,,US-MACLEODS PHARMA-MAC2024048349,MACLEODS,"Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D Agati VD, Markowitz GS.Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.Kidney international.2010;78(11):1171-7",63,YR,A,M,Y,,,20240723,,HP,US,US,EFAVIRENZ,Post infection glomerulonephritis;Renal tubular necrosis,241253171,OT,,,241253171,1,,,8,,241253171,1,HIV infection
24125324,241253241,1,I,,20240710,20240723,20240723,EXP,,US-MACLEODS PHARMA-MAC2024048352,MACLEODS,"Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D^Agati VD, Markowitz GS.Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.Kidney international.01-DEC-2010;78(11):1171-7",,,,,Y,,,20240723,,HP,US,US,EFAVIRENZ,Intercapillary glomerulosclerosis;Renal tubular disorder,241253241,OT,,,241253241,1,,,8,,241253241,1,HIV infection
24125664,241256641,1,I,,20240712,20240723,20240723,EXP,,DK-AUROBINDO-AUR-APL-2024-035672,AUROBINDO,"Pedersen OS, Barkholt TO, Madsen SH, Rudolf F.. Tuberculosis immune reconstitution syndrome (TB-IRIS) followed by recurring lymphadenitis up to 8 years post-antituberculous treatment.. BMJ Case Reports.. 2024;17 (6)",,,A,F,Y,,,20240723,,HP,DK,DK,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis;Lymphadenitis;Lymphadenopathy;Oral candidiasis;Pyrexia;Renal impairment,241256641,HO,,,,,,,,,241256641,1,HIV infection
24131381,241313811,1,I,,20240715,20240724,20240724,EXP,,UG-MYLANLABS-2024M1068084,MYLAN,"Nambuya M, Mayanja-Kizza H. A case report: recurrent anemia related to long term acyclovir use in a pregnant HIV infected Ugandan. Afr-Health-Sci 2024; 24 (1): 91-93.",19,YR,,F,Y,,,20240724,,HP,UG,UG,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Disease recurrence;Intentional product misuse;Maternal exposure during pregnancy;Off label use;Treatment noncompliance,241313811,HO,,,,,,,,,241313811,1,Anogenital warts
24131564,241315641,1,I,,20240716,20240724,20240724,EXP,,ZW-MYLANLABS-2024M1068111,MYLAN,"Mandikiyana Chirimuta LA, Pascoe MJ, Lowe S. Emergent dolutegravir resistance in integrase-naive, treatment experienced patients from Zimbabwe. South-Afr-J-HIV-Med 2022; 23 (1): a1435.",7,YR,,M,Y,,,20240724,,HP,ZW,ZW,EFAVIRENZ\LAMIVUDINE\STAVUDINE;EFAVIRENZ\LAMIVUDINE\ZIDOVUDINE,Drug resistance mutation;Treatment failure,241315641,OT,,,241315641,1,201009,201501,,,241315641,1,HIV infection
24131625,241316251,1,I,,20240717,20240724,20240724,EXP,,DK-MYLANLABS-2024M1067358,MYLAN,"Pedersen OS, Barkholt TO, Madsen SH, Rudolf F.. Tuberculosis immune reconstitution syndrome (TB-IRIS) followed by recurring lymphadenitis up to 8 years post-antituberculous treatment.. BMJ Case Reports.. 2024;17 (6)",,,A,F,Y,,,20240724,,HP,DK,DK,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis;Lymphadenitis;Lymphadenopathy;Oral candidiasis;Pyrexia;Renal impairment,241316251,OT,,,,,,,,,241316251,1,HIV infection
24134656,241346561,1,I,,20240717,20240725,20240725,EXP,GB-MHRA-MED-202407171329112380-FHGCW,GB-AMAROX PHARMA-AMR2024GB02339,HETERO,,,,,F,Y,,,20240725,,HP,GB,GB,EFAVIRENZ,Choking;Dyspnoea;Foreign body in throat;Presyncope,241346561,OT,,,,,,,,,241346561,1,Product used for unknown indication
24139311,241393111,1,I,,20240715,20240726,20240726,EXP,,UG-STRIDES ARCOLAB LIMITED-2024SP009079,STRIDES,"Nambuya M, Mayanja-Kizza H.. A case report: recurrent anemia related to long term acyclovir use in a pregnant HIV infected Ugandan.. Afr-Health-Sci. 2024;24(1):91-93",19,YR,,F,Y,,,20240726,,HP,UG,UG,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Disease recurrence;Intentional product misuse;Maternal exposure during pregnancy;Treatment noncompliance,241393111,HO,,,,,,,,,241393111,1,Anogenital warts
24139944,241399441,1,I,,20240711,20240726,20240726,EXP,,UG-CPL-004448,CADILA,"Nambuya M, Mayanja-Kizza H. A case report: recurrent anemia related to long term acyclovir use in a pregnant HIV infected Ugandan. Afr Health Sci. 2024 Mar;24(1):91-93.",19,YR,A,F,Y,,,20240726,,HP,UG,UG,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia megaloblastic;Maternal exposure during pregnancy,241399441,HO,,,,,,,,,241399441,1,Anogenital warts
24140173,241401732,2,F,,20240730,20240726,20240809,EXP,,GB-AUROBINDO-AUR-APL-2024-035747,AUROBINDO,,,,,F,Y,,,20240809,,HP,GB,GB,EFAVIRENZ,Choking;Dyspnoea;Foreign body in throat;Presyncope,241401732,OT,,,,,,,,,241401732,1,Product used for unknown indication
24149413,241494132,2,F,,20240730,20240730,20240731,EXP,GB-MHRA-MED-202407171329112380-FHGCW,GB-BRISTOL-MYERS SQUIBB COMPANY-2024-114135,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20240731,,HP,GB,GB,EFAVIRENZ,Choking;Dyspnoea;Foreign body in throat;Presyncope,241494132,OT,,,,,,,,,241494132,1,Product used for unknown indication
24151140,241511401,1,I,,20240715,20240730,20240730,EXP,,UG-SUN PHARMACEUTICAL INDUSTRIES LTD-2024RR-459486,RANBAXY,"Nambuya M, Mayanja-Kizza H. A case report: recurrent anemia related to long term acyclovir use in a pregnant HIV infected Ugandan. Afr Health Sci. 2024;24 (1):91-93",19,YR,,F,Y,,,20240730,,HP,UG,UG,EFAVIRENZ,Anaemia;Drug ineffective;Exposure during pregnancy,241511401,OT,,,,,,,,,241511401,1,Anogenital warts
24154539,241545391,1,I,,20240723,20240731,20240731,EXP,,BR-STRIDES ARCOLAB LIMITED-2024SP009362,STRIDES,"Muller PR, Coelho ADC, da Cruz VIF, Barros DDO, Bertolini DV.. PERFIL DO AMBULATORIO DE PRE NATAL (CIS E TRANS) DE PESSOAS GESTANTES QUE VIVEM COM HIV (PGVHIV) OU PESSOAS GESTANTES DE PARCERIAS SORODIFERENTES (PGPSD), INCLUINDO HOMENS TRANSEXUAIS NO CRT DST-AIDS SP E SEU IMPACTO SOBRE A TRANSMISSAO VERTICAL.. Brazil-J-Infect-Dis. 2023;27 (Suppl.):no pagination",,,,F,Y,,,20240731,,HP,BR,BR,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,241545391,OT,,,,,,,,,241545391,1,HIV infection
24155899,241558991,1,I,,20240720,20240731,20240731,EXP,,US-AUROBINDO PHARMA GMBH-AUR-APL-2014-05905,AUROBINDO,803103150,12,YR,,M,Y,,,20240731,,HP,US,US,EFAVIRENZ,Dyspnoea;Immune reconstitution inflammatory syndrome;Neuropathy peripheral;Pericardial effusion;Skin lesion,241558991,OT,,,,,,,,,241558991,1,Antiretroviral therapy
24156903,241569031,1,I,,20240722,20240731,20240731,EXP,,US-MYLANLABS-2024M1069413,MYLAN,"Woods HB, Bharathidasan K, Yang M, Nichols J, Nugent K. Delayed onset graves disease following initiation of antiretroviral therapy in patients with human immunodeficiency virus: a case series. Am-J-Med-Sci 2024; 367 (Suppl. 1) S9-S10.",51,YR,,F,Y,,,20240731,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Endocrine ophthalmopathy;Graves' disease,241569031,HO,,,,,,,,,241569031,1,HIV infection
24160675,241606751,1,I,,20231108,20240801,20240801,EXP,,CN-ALKEM LABORATORIES LIMITED-CN-ALKEM-2023-14175,ALKEM,"Liu YY, Song Y, Guan MQ, Yang L, Chen RL, Shi Y, Cui Y, Li SS.. Hyperthermia is a Promising Potential Adjunct to Treating Sporotrichosis: A Refractory Case of HIV Sporotrichosis and In Vitro Experiments on Sporothrix spp. Mycoses. 2023;unk:unk",44,YR,,M,Y,,,20240801,,MD,CN,CN,EFAVIRENZ,Therapy non-responder,,,,,241606751,2,,,6,MON,241606751,1,Cutaneous sporotrichosis
24165769,241657691,1,I,,20240725,20240802,20240802,EXP,,UG-NOVITIUMPHARMA-2024UGNVP01452,NOVITIUM PHARMA,Mariam Nambuya. A case report: recurrent anemia related to long term acyclovir use in a pregnant HIV infected Ugandan.African Health Sciences.01-APR-2024;24(1):91-93,19,YR,A,F,Y,,,20240802,,HP,UG,UG,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Exposure during pregnancy;Intentional product misuse;Treatment noncompliance,241657691,HO,,,,,,,,,241657691,1,Anogenital warts
24169783,241697831,1,I,,20240722,20240803,20240803,EXP,,UG-AUROBINDO-AUR-APL-2024-037630,AUROBINDO,"Nambuya M, Mayanja-Kizza H.. A case report: recurrent anemia related to long term acyclovir use in a pregnant HIV infected Ugandan. Afr-Health-Sci. 2024;24(1):91-93",19,YR,,F,Y,,,20240803,,HP,UG,UG,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE",Anaemia;Anogenital warts;Genital haemorrhage;Intentional product misuse;Malaria;Productive cough;Treatment noncompliance,241697831,OT,,,,,,,,,241697831,1,Anogenital warts
24191423,241914232,2,F,,20240812,20240808,20240820,EXP,,US-TEVA-VS-3228835,TEVA,"Woods HB, Bharathidasan K, Yang M, Nichols J, Nugent K. Delayed onset graves disease following initiation of antiretroviral therapy in patients with human immunodeficiency virus: a case series. Am-J-Med-Sci 2024; 367 (Suppl. 1) S9-S10.; Woods HB, Bharathidasan K, Yang M, Nichols J, Nugent K. Delayed onset graves disease following initiation of antiretroviral therapy in patients with human immunodeficiency virus: a case series. Am-J-Med-Sci 2024; 367 (Suppl. 1) S9-S10.",51,YR,,F,Y,,,20240820,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Endocrine ophthalmopathy;Graves' disease,241914232,HO,,,,,,,,,241914232,1,HIV infection
24191587,241915872,2,F,,20240819,20240808,20240831,EXP,,US-AUROBINDO-AUR-APL-2024-038821,AUROBINDO,"Woods HB, Bharathidasan K, Yang M, Nichols J, Nugent K.. Delayed onset graves disease following initiation of antiretroviral therapy in patients with human immunodeficiency virus: a case series. Am-J-Med-Sci. 2024;367 (Suppl. 1):S9-S10",51,YR,,F,Y,,,20240831,,MD,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Endocrine ophthalmopathy;Graves' disease;Immune reconstitution inflammatory syndrome,241915872,OT,,,,,,,,,241915872,1,HIV infection
24203483,242034831,1,I,,20240805,20240813,20240813,EXP,,ZA-AstraZeneca-2024A180032,ASTRAZENECA,,39,YR,,M,Y,,,20240813,,CN,ZA,,EFAVIRENZ\EMTRICITABINE\TENOFOVIR\TENOFOVIR DISOPROXIL FUMARATE,Cardiac failure;Muscle spasms;Viral infection,242034831,OT,,,,,,,,,242034831,1,Diabetes mellitus
24208222,242082221,1,I,,20240802,20240814,20240814,EXP,,CA-AUROBINDO-AUR-APL-2024-040193,AUROBINDO,,63,YR,,M,Y,,,20240814,,HP,CA,CA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR,Acute kidney injury;Dialysis,242082221,HO,,,242082221,1,,,3,YR,242082221,1,Product used for unknown indication
24208773,242087731,1,I,20180601,20240802,20240814,20240814,EXP,,UG-MYLANLABS-2024M1073734,MYLAN,"Lubega G, Lutaakome J, Kibirige M, Opoka D, Atukunda I, Ruzagira E. Vitamin B12 deficiency presenting as progressive blindness in a 33-year-old HIV-positive female patient on Efavirenz-based regimen: case report. Pan-Afr-Med-J 2024; 47 (0): 164.",30,YR,,F,Y,,,20240814,,HP,UG,UG,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Neuropathy peripheral;Optic neuritis;Vitamin B12 deficiency,242087731,OT,,,242087731,1,201301,2015,2,WK,242087731,1,HIV infection
24210181,242101811,1,I,,20240813,20240814,20240814,EXP,,US-GILEAD-2024-0684151,GILEAD,,39,YR,A,M,Y,,,20240814,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Feeling abnormal;Rash,242101811,HO,,,242101811,1,2016,2016,,,242101811,1,HIV infection
24214385,242143851,1,I,,20240805,20240815,20240815,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2024GSK099062,VIIV,,,,,,Y,,,20240815,,HP,IT,IT,EFAVIRENZ,Hypertension;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure;Weight increased,242143851,OT,,,242143851,1,201402,201506,,,242143851,1,HIV infection
24214388,242143881,1,I,,20240805,20240815,20240815,EXP,,IT-GSK-IT2024GSK099062,GLAXOSMITHKLINE,,,,,,Y,,,20240815,,HP,IT,IT,EFAVIRENZ,Hypertension;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure;Weight increased,242143881,OT,,,242143881,1,201402,201506,,,242143881,1,HIV infection
24221940,242219401,1,I,,20240805,20240819,20240819,EXP,,ZA-CIPLA LTD.-2024ZA08705,CIPLA,"Bishop MD, Frenkel LM, Korutaro V, Boyce CL, Beck IA, Styrchak SM et al.. Characterizing HIV drug resistance in cases of vertical transmission in the VesTed randomized antiretroviral treatment trial. J Acquir Immune Defic Syndr. 2024;96 (4):385 to 392",,,,,Y,,,20240819,,HP,ZA,ZA,EFAVIRENZ,Death neonatal;Foetal exposure during pregnancy,242219401,DE,,,,,,,,,,,
24229546,242295461,1,I,20240517,20240813,20240820,20240820,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2024APC100933,VIIV,,,,,,Y,,,20240820,,HP,CN,CN,EFAVIRENZ,Condition aggravated;Drug hypersensitivity;Osteoporosis;Petechiae;Pruritus;Rash erythematous;Rash pruritic,242295461,HO,,,242295461,1,20240701,20240705,4,DAY,242295461,1,Acquired immunodeficiency syndrome
24229548,242295481,1,I,20240517,20240813,20240820,20240820,EXP,,CN-GSK-CN2024APC100933,GLAXOSMITHKLINE,,,,,,Y,,,20240820,,HP,CN,CN,EFAVIRENZ,Condition aggravated;Drug hypersensitivity;Osteoporosis;Petechiae;Pruritus;Rash erythematous;Rash pruritic,242295481,HO,,,242295481,1,20240701,20240705,4,DAY,242295481,1,Acquired immunodeficiency syndrome
24230742,242307421,1,I,20180602,20240813,20240821,20240821,EXP,,UG-DEXPHARM-2024-2866,DEXCEL,"Lubega, G.; Lutaakome, J.; Kibirige, M.; Opoka, D.; Atukunda, I.; Ruzagira, E.  Vitamin B12 deficiency presenting as progressive blindness in a 33-year- old HIV-positive female patient on Efavirenz-based regimen: case report. Pan African Medical Journal 2024, V47, P164",33,YR,A,F,Y,,,20240821,,HP,UG,UG,EFAVIRENZ,Optic neuritis;Vitamin B12 deficiency,242307421,HO,,,242307421,1,201301,,2,WK,242307421,1,HIV infection
24235546,242355461,1,I,,20240819,20240822,20240822,EXP,,IT-JNJFOC-20240850285,JOHNSON AND JOHNSON,,60,YR,A,F,Y,,,20240822,,HP,IT,IT,EFAVIRENZ,Hypertension;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure;Weight increased,242355461,OT,,,242355461,1,200910,202007,,,242355461,1,HIV infection
24253884,242538842,2,F,,20240823,20240827,20240829,EXP,,ID-PFIZER INC-202400242265,PFIZER,"Sufiawati, I.. Case Series of HIV-Associated Oral Lesions Across Different Clinical Stages in People Living with HIV. HIV/AIDS - Research and Palliative Care. 2024;16:289-299",34,YR,,F,Y,,,20240829,,MD,ID,ID,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Angular cheilitis;Drug eruption;Erythema multiforme,242538842,OT,,,,,,,,,242538842,6,Antiretroviral therapy
24254578,242545782,2,F,,20240821,20240827,20240830,EXP,,IT-MYLANLABS-2024M1077815,MYLAN,"Monti B, Soria A, Saladini F, Lapadula G, Squillace N, Giammarino F, et al.. Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests.. Journal of Medical Virology.. 2024;96(8)",60,YR,,F,Y,,,20240830,,HP,IT,IT,EFAVIRENZ,Hypertension;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure;Weight increased,242545782,OT,,,242545782,1,201805,201909,,,242545782,1,HIV infection
24257651,242576512,2,F,20221201,20240830,20240828,20240910,EXP,,IT-AUROBINDO-AUR-APL-2024-042100,AUROBINDO,"Monti B, Soria A, Saladini F, Lapadula G, Squillace N, Giammarino F, et al. Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests. Journal of Medical Virology. 2024;96(8):1-3.",60,YR,,F,Y,,,20240910,,HP,IT,IT,EFAVIRENZ,Drug resistance;Hypertension;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure;Weight increased,242576512,OT,,,242576512,1,200901,200910,,,242576512,1,HIV infection
24259122,242591221,1,I,,20240821,20240828,20240828,EXP,,ID-PERRIGO-24ID007900,PERRIGO,"Permatasanti A, Sufiawati I. Case Series of HIV-Associated Oral Lesions Across Different Clinical Stages in People Living with HIV. HIV/AIDS - Research and Palliative Care. 2024;16:289-99. DOI:10.2147/HIV.S478366.",34,YR,,F,Y,,,20240828,,MD,ID,ID,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Angular cheilitis;Drug eruption;Erythema multiforme,242591221,OT,,,,,,,,,242591221,1,Product used for unknown indication
24267665,242676651,1,I,,20240819,20240830,20240830,EXP,,US-MACLEODS PHARMA-MAC2024048991,MACLEODS,"Woods HB, Bharathidasan K, Yang M, Nichols J, Nugent K..Delayed onset Graves disease following initiation of antiretroviral therapy in patients with human immunodeficiency  virus: A case series.American Journal of the Medical Sciences.2024;367(Suppl 1):S9-10",,,,,Y,,,20240830,,MD,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR,Endocrine ophthalmopathy;Graves' disease;Immune reconstitution inflammatory syndrome,242676651,OT,,,,,,,,,242676651,1,HIV infection
24280532,242805321,1,I,,20240903,20240904,20240904,EXP,GB-MHRA-MED-202409020906128010-ZDPHQ,GB-GILEAD-2024-0686092,GILEAD,,,,,M,Y,,,20240904,,HP,GB,GB,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Renal disorder,242805321,OT,,,,,,,,,242805321,1,Product used for unknown indication
24294315,242943151,1,I,,20240903,20240906,20240906,EXP,GB-MHRA-MED-202409020906128010-ZDPHQ,GB-BRISTOL-MYERS SQUIBB COMPANY-2024-141909,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20240906,,HP,GB,GB,EFAVIRENZ,Renal disorder,242943151,OT,,,,,,,,,242943151,1,Product used for unknown indication
24294405,242944051,1,I,,20240904,20240906,20240906,EXP,GB-MHRA-MED-202409031429539670-ZJPQL,GB-GILEAD-2024-0686216,GILEAD,,,,,M,Y,,,20240906,,HP,GB,GB,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance,242944051,OT,,,,,,,,,242944051,1,Product used for unknown indication
24298687,242986871,1,I,,20240903,20240909,20240909,EXP,GB-MHRA-MED-202409020906128010-ZDPHQ,GB-MYLANLABS-2024M1081451,MYLAN,,,,,M,Y,,,20240909,,HP,GB,GB,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Renal disorder,242986871,OT,,,,,,,,,242986871,1,Product used for unknown indication
24306351,243063511,1,I,,20240829,20240911,20240911,EXP,,ZA-MACLEODS PHARMA-MAC2024049204,MACLEODS,"Bishop MD, Korutaro V, Boyce CL, Beck IA, Styrchak SM, Knowles K, Ziemba L, Brummel SS, Coletti A, Jean-Philippe P, Chakhtoura N..Characterizing HIV Drug Resistance in Cases of Vertical Transmission in the VESTED Randomized Antiretroviral Treatment Trial.JAIDS Journal of Acquired Immune Deficiency Syndromes.2024;96(4):385-392",,,,,Y,,,20240911,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR,Death neonatal;Foetal exposure during pregnancy,243063511,DE,,,,,,,,,243063511,1,Product used for unknown indication
24311016,243110161,1,I,,20240904,20240912,20240912,EXP,,ZA-AstraZeneca-2024A204630,ASTRAZENECA,,69,YR,,M,Y,,,20240912,,CN,ZA,,EFAVIRENZ\EMTRICITABINE\TENOFOVIR\TENOFOVIR DISOPROXIL FUMARATE,Neoplasm malignant,243110161,HO,,,,,,,,,243110161,1,Diabetes mellitus
24317648,243176481,1,I,,20240903,20240913,20240913,EXP,GB-MHRA-MED-202409020906128010-ZDPHQ,GB-AMAROX PHARMA-AMR2024GB02960,HETERO,,,,,M,Y,,,20240913,,HP,GB,GB,EFAVIRENZ,Renal disorder,243176481,OT,,,,,,,,,243176481,1,Product used for unknown indication
24318474,243184741,1,I,,20240904,20240913,20240913,EXP,GB-MHRA-MED-202409031429539670-ZJPQL,GB-HETERO-AMR2024GB02991,HETERO,,,,,M,Y,,,20240913,,HP,GB,GB,EFAVIRENZ,Drug resistance,243184741,OT,,,,,,,,,243184741,1,Product used for unknown indication
24322709,243227091,1,I,,20240903,20240916,20240916,EXP,GB-MHRA-MED-202409020906128010-ZDPHQ,GB-MACLEODS PHARMA-MAC2024049273,MACLEODS,,,,,,Y,,,20240916,,HP,GB,GB,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Renal disorder,243227091,OT,,,,,,,,,243227091,1,Product used for unknown indication
24324308,243243081,1,I,,20240903,20240916,20240916,EXP,,GB-CIPLA LTD.-2024GB09800,CIPLA,,,,,,Y,,,20240916,,HP,GB,GB,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Renal disorder,243243081,OT,,,,,,,,,243243081,1,Product used for unknown indication
24327102,243271021,1,I,,20240904,20240917,20240917,EXP,GB-MHRA-MED-202409031429539670-ZJPQL,GB-MACLEODS PHARMA-MAC2024049299,MACLEODS,,,,,M,Y,,,20240917,,HP,GB,GB,EFAVIRENZ,Drug resistance,243271021,OT,,,,,,,,,243271021,1,Product used for unknown indication
24327264,243272641,1,I,,20240912,20240917,20240917,EXP,,ZA-AstraZeneca-2024A209698,ASTRAZENECA,,52,YR,,M,Y,,,20240917,,CN,ZA,,EFAVIRENZ\EMTRICITABINE\TENOFOVIR\TENOFOVIR DISOPROXIL FUMARATE,Stress,243272641,HO,,,,,,,,,243272641,1,Diabetes mellitus
24330906,243309061,1,I,20240904,20240913,20240918,20240918,EXP,,ZA-AstraZeneca-2024A211396,ASTRAZENECA,,73,YR,,M,Y,,,20240918,,CN,ZA,,ADCO-EFAVIRENZ,Death,243309061,DE,,,,,,,,,243309061,1,Asthma
24337850,243378501,1,I,,20240909,20240919,20240919,EXP,,CA-APOTEX-2024AP010378,APOTEX,,,,,M,Y,,,20240919,,CN,CA,CA,EFAVIRENZ,Depression;Drug interaction,243378501,DE,,,,,,,,,243378501,1,Product used for unknown indication
24354283,243542831,1,I,,20240920,20240923,20240923,EXP,,CA-GILEAD-2024-0688514,GILEAD,,54,YR,A,M,Y,,,20240923,,HP,CA,CA,EFAVIRENZ,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Product use in unapproved indication;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,243542831,HO,,,,,,,,,243542831,1,Product used for unknown indication
24355635,243556351,1,I,,20240918,20240924,20240924,EXP,,ZW-CIPLA LTD.-2024ZW08707,CIPLA,"Bishop MD, Frenkel LM, Korutaro V, Boyce CL, Beck IA, Styrchak SM et al.. Characterizing HIV drug resistance in cases of vertical transmission in the VesTed randomized antiretroviral treatment trial. J Acquir Immune Defic Syndr. 2024;96 (4):385 to 392",,,,,Y,,,20240924,,HP,ZW,ZW,EFAVIRENZ,Drug ineffective;Exposure during pregnancy;HIV viraemia;Treatment noncompliance,243556351,OT,,,,,,,,,243556351,1,Antiretroviral therapy
24380831,243808311,1,I,,20240925,20240930,20240930,EXP,,CA-BAUSCH-BL-2024-014456,BAUSCH AND LOMB,,,,,M,Y,,,20240930,,CN,CA,CA,EFAVIRENZ,Depression;Drug interaction,243808311,DE,,,,,,,,,243808311,1,Product used for unknown indication
7155921,715592116,16,F,,20240611,20091022,20240708,EXP,,CA-ROCHE-663583,ROCHE,"PFEFFER G, Pfeffer G, Cote H, Montaner J, Li C, Jitratkosol M and Mezei M. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY 2009 Jul 07;73 (1):71-72.",52,YR,A,M,Y,,,20240709,,MD,CA,CA,EFAVIRENZ,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,715592116,OT,,,715592116,1,,,457,DAY,715592116,1,HIV infection
7686793,768679327,27,F,20070423,20240902,20101130,20240911,EXP,,JP-JNJFOC-20101108379,JOHNSON AND JOHNSON,,28,YR,A,M,Y,,,20240911,,MD,JP,JP,EFAVIRENZ,Abdominal distension;Atrioventricular block second degree;Blood triglycerides increased;Bradycardia;Campylobacter gastroenteritis;Dyslipidaemia;Gastrointestinal haemorrhage;Haemoglobin decreased;Haemorrhoids;Hepatic function abnormal;Herpes zoster;Liver function test abnormal;Liver function test increased;Malaise;Oropharyngeal discomfort;Tachycardia paroxysmal,768679327,HO,,,768679327,1,20060905,20181001,12,YR,768679327,1,HIV infection
